Market Overview

UPDATE: Credit Suisse Upgrades Medtronic to Outperform on Growth Outlook

Related MDT
Covidien Earnings Preview: Has Merger News Shaken Expectations?
5 New Medical Technologies For Diabetics
FT: 25 More Firms May Seek Tax Breaks Overseas (Fox Business)

Credit Suisse upgraded Medtronic (NYSE: MDT) from Neutral to Outperform and raised the price target from $47.00 to $50.00.

Credit Suisse noted, "MDT's F2H13 & F14 growth aspirations indicate increased confidence that the last 2 quarters of ~5% WW CC growth represent sustainable improvement relative to the flattish top-line growth reported in FY11 & FY12 and further suggest that the growth-oriented acquisitions (Peak, Salient, KH) and increased emerging markets focus that have taken place during CEO Omar Ishrak's early tenure with the company are moving MDT in the right strategic direction."

Medtronic closed at $43.94 on Wednesday.

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Most Popular

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters